SCHEMBL10043859

SCHEMBL10043859

Cc1cc2c(cn1)cc(-c1cc(NC(=O)NC(=O)c3ccc(Br)cc3)ccc1C)c(=O)n2C

nearest known ligand 0.42

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SYK P43405 1/20 0.42
POLB P06746 1/20 0.39
MAPT P10636 1/20 0.39
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
ATM Q13315 1/20 0.37
MAPK14 Q16539 4/20 0.37
FGFR1 P11362 1/20 0.36
SRC P12931 1/20 0.36
ABL1 P00519 5/20 0.35
RXFP1 Q9HBX9 1/20 0.35
HDAC8 Q9BY41 1/20 0.35
DUSP1 P28562 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10043857 0.94 POLB (0.45) SYKPOLBMAPTNPC1RAB9A
SCHEMBL13462639 0.91 SYK (0.42) SYKPOLBMAPTNPC1RAB9A
SCHEMBL10043869 0.91 GAA (0.45) SYKPOLBMAPTNPC1RAB9A
SCHEMBL10043851 0.91 PCTP (0.44) SYKPOLBMAPTNPC1RAB9A
SCHEMBL10043850 0.91 SYK (0.50) SYKPOLBMAPTNPC1RAB9A
SCHEMBL10043860 0.90 SYK (0.51) SYKNPC1RAB9AMAPK14ABL1
SCHEMBL502302 0.90 FGFR1 (0.44) SYKMAPTNPC1RAB9AMEN1
SCHEMBL10043856 0.89 MAPK14 (0.42) SYKPOLBMAPTNPC1RAB9A
SCHEMBL10043948 0.88 MAPK14 (0.42) SYKPOLBMAPTNPC1RAB9A
SCHEMBL10043875 0.88 RAB9A (0.43) SYKPOLBMAPTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106068-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2012-01-31 US disclosed
US-8106068-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2012-01-31 US disclosed
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2010-04-01 US disclosed
US-7678792-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2010-03-16 US disclosed
US-7678792-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2010-03-16 US disclosed
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2008-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC SYK 42/4885POLB 4382/4885MAPT 2514/4885
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC SYK 42/4885POLB 4382/4885MAPT 2514/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.